It is very uncertain whether CLOZAPINE + RISPERIDONE changes adverse effects: weight gain compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether COMPARISON 4. ARIPIPRAZOLE changes adverse effects: weight gain compared with ZIPRASIDONE (very low certainty).
It is very uncertain whether COMPARISON 5. ARIPIPRAZOLE changes adverse effects: weight gain compared with OLANZAPINE (very low certainty).
CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain compared with CLOZAPINE ‐ all data short term (low certainty).
QUETIAPINE probably leads to lower adverse effects: 3. Metabolic ‐ weight significant gain compared with OLANZAPINE (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with PALIPERIDONE (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with RISPERIDONE (moderate certainty).
QUETIAPINE probably leads to higher adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with ZIPRASIDONE (moderate certainty).
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain ≥7% of total body weight compared with ARIPIPRAZOLE (low certainty).
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).